Aristotelis Bamias MEDICAL ONCOLOGY

• National & Kapodistrian University of Athens  “Immunohistochemical study of colon cancer with monocloncal antibodies. Comparison of antigenic expression of adenomas and cancer of the colon”

• University of London “The development of a prodrug activation system for cancer therapy”

• Member of the Royal College of Physicians (UK)

• Internal Medicine, Ministry of Health, Greece

• Medical Oncology, Ministry of Health, Greece

Editorial Boards

• Associate Editor – European Journal of Cancer Care

• Editorial Board – Experimental Hematology & Oncology

• September 2023, Associate Physician

• 9 September 2019-8 Septemeber 2022, Director 2nd Propaedeutic Dept of Internal Medicine, Medical School, University of Athens, ATTIKON University Hospital)

• 7 October 2016-cont’d, Professor of Therapeutics-Medicine-Oncology Medical School, Universi-ty of Athens

• 3 September 2012-6 October 2016, Associate Professor, Medical School, University of Athens

• 28 August 2007-2 September 2012, Assistant Professor, Medical School, University of Athens

• 8 October 2002-27 August 2007, Lecturer Medical School, University of Athens

• 27 March 1997- 7 October 2002, Consultant in Medical Oncology, University Hospital, Ioannina, Greece

• 1 March 1995-31 November 1995, Lecturer /Honorary Registrar in Medical Oncology, St. Bartholomews Hospital, London

• 1 September 1994-28 February 1995, SHO in General Medicine/Neurology, Oldhurch Hospital, London

• 1 February 1994-31 August 1994, Clinical Research Fellow in GI and Lymphoma Unit, Royal Marsden Hospi-tal, Sutton

• 1 August 1993-31 January 1994, SHO in General Medicine/Oncology, Royal Marsden Hospital, Sutton

• 1 February 1993-31 July 1993, SHO in General Medicine, Northern General Hospital, Sheffield

• 25 June 1988-31 January 1993, Research Fellow/PhD student Dept of Clinical Oncology, Hammersmith Hospital, University of London

• 17 August 1987-20 June 1988, SHO in General Medicine, 3rd Internal Medicine Dept, Agii Anargyri Hos-pital, Athens

• 26 May 1987-16 August 1987, SHO in General Medicine, Evanghelismos Hospital, Athens

Education Experience

• Undergraduate Education Medical School, University of Athens  

6th semester (teaching subject: mandatory course of Clinical ex-amination)

7th semester (teaching subject: mandatory course of Medicine)

9th-10th semester (teaching subject: mandatory course of Thera-peutics)

11th-12th semester (teaching subject: Internal Medicine)

Faculty member in charge of the elective course “ONCOLOGY I” (2007-2015)

Teaching of the elective course of “Gynaecological Oncology” (2011-2019)

Teaching of the 3rd Summer School of Oncology, participants: students of the 5th year of all Greek Medical Schools (2009)

Tutor in CIVIS International programme

• Postgraduate Education

Residents in Internal Medicine

Residents in Medical Oncology

Residents in Urology

Teaching at 4 Postgraduate Courses of the Medical School, Uni-versity of Athens

Academy of the European Society of Medical Oncology 

Clinical Interest: Genitourinary cancers, Gynaecological cancers  

Research Interest:  Genitourinary cancers, Gynaecological cancers, Immunology and immunotherapy of Cancer

• Included among the most cited Greek scientists (Edition Kedros: «Tracta-tus για την έκτη φήμη» by John Ioannides, Professor of Biostatistics, Stan-ford University, pages 62-75, list available upon request)

• Member of the Faculty of the Educational Committee of the European School of Medical Oncology (ESMO)-Genitourinary Group (2012-cont’d). Co-ordinator of the Group 2016-2020.

• Invited Professor by the Oncology Dept, Hopital Universitaire de Geneve for Urogenital Cancer (March-August 2012)

• Member of the international Panel of Experts for the Guidelines for the management of prostate cancer (2007)

• Member of the ESMO Guidelines Working Group for testicular cancer (2008).

• European Medicinal Agency (EMA) expert for the Greek National Drug Organisation (EOF)

• Invited Reviewer of funding applications to international organizations (Austrian Science Fund, Health and Medical Research Fund Hong Kong, Italian Association of Medical Oncology [AIOM])

• Grande E, Bamias A, Galsky MD, Kikuchi E, Davis ID, Arranz JÁ, Rezazadeh Kalebasty A, Garcia Del Muro X, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Puente J, Li JR, Bernhard S, Nicholas A, Telliez J, De Santis M. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma. Eur Urol Open Sci. 2023;58:28-36

• van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389:1778-1789.

• Bamias A, Stenzl A, Zagouri F, Andrikopoulou A, Hoskin P. Defining Oligometastatic Bladder Cancer: A Systematic Review. Eur Urol Open Sci. 2023;55:28-37

• Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, Briganti A, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Loriot Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P, Pinkawa M, Ribal MJ, Rouprêt M, Thoeny H, Zilli T, Hoskin P. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023;84:381-389.

• Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023;29:4373-4384.

• Bamias A, Merseburger A, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. J Immunother Cancer. 2023;11:e005977. 

• Bamias A, Tzannis K, Zakopoulou R, Sakellakis M, Dimitriadis J, Papatheodoridi A, Rallidis L, Halvatsiotis P, Tsiara A, Kaparelou M, Kostouros E, Barbarousi D, Koutsoukos K, Fragiadis E, Dellis AE, Anastasiou I, Stravodimos K, Pinitas A, Papatsoris A, Adamakis I, Varkarakis I, Fragoulis C, Pagoni S, Matsouka C, Skolarikos A, Mitropoulos D, Doumas K, Deliveliotis C, Constantinides C, Dimopoulos MA. Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study. Curr Oncol. 2022;29:6077-6090. 

• van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA, Bamias A, Gakis G, Lee JL, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Eigl BJ, Hozak RR, Rasmussen ER, Xia MS, Rhodes R, Wijayawardana S, Bell-McGuinn KM, Aggarwal A, Drakaki A. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nat Commun. 2022;13:1878

• Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384:2102-2114

• Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thåström A, Grande E; IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557